DCGI approves Themis Medicare's Viralex for Covid-19 treatment
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Scientists worldwide have started employing wastewater analysis as an efficient and cost-effective approach for assessing the dynamics of the virus in a population. Several scientific methods are being developed to rapidly decode the message carried by sewage
High level of vaccine efficacy maintained over a 6-month period of surveillance
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
100% efficacy against severe Covid-19 disease and hospitalizations
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Subscribe To Our Newsletter & Stay Updated